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Objective: Epidemiological research plays an important role in public health, facili-
tated by the meta‐analytic aggregation of epidemiological trials into a single, more
powerful estimate. This form of aggregation is complicated when estimating the prev-
alence of a superordinate category of disorders (e.g., “any anxiety disorder,” “any car-
diac disorder”) because epidemiological studies rarely include all of the disorders
selected to define the superordinate category. In this paper, we suggest that estimat-
ing the prevalence of a superordinate category based on studies with differing
operationalization of that category (in the form of different disorders measured) is
both common and ill‐advised. Our objective is to provide a better approach.
Methods: We propose a multivariate method using individual disorder prevalences
to produce a fully Bayesian estimate of the probability of having one or more of those
disorders. We validate this approach using a recent case study and parameter recov-
ery simulations.
Results: Our approach produced less biased and more reliable estimates than other
common approaches, which were at times highly biased.
Conclusion: Although our approach entails additional effort (e.g., contacting authors
for individual participant data), the improved accuracy of the prevalence estimates
obtained is significant and therefore recommended.
KEYWORDS
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2 of 13 FAWCETT ET AL.Mazmanian, 2016; Russell, Fawcett, & Mazmanian, 2013; Simpson,
Blizzard, Otahal, Van der Mei, & Taylor, 2011). Bayesian techniques
are often used due to their flexibility and capacity to produce a cred-
ible estimate of beliefs given data from multiple sources (e.g., Ades &
Sutton, 2006; Greenland, 2006).
Whereas aggregating individual disorder estimates is routine, it is
unclear how tomodel the prevalence of superordinate categories—such
as “any anxiety disorder” or “any cardiac disorder”—operationalized by
combining multiple underlying conditions. We focus on an example
from mental health, but our methods apply to any superordinate cate-
gory. Within the health professions, superordinate categories play an
important role by easing the interpretation and categorization of related
symptoms and simplifying the identification of at‐risk populations with-
out becoming lost in the minutiae of individual disorders. They also
serve important social functions. For example, nonexperts better com-
prehend broad statements (one in five women suffer from anxiety dis-
orders) than more specialized statements (one in 10 women suffer
from social anxiety). Superordinate estimates therefore help generate
the “big picture” within which public campaigns are most effective.
One challenge is that the category itself is often operationalized
differently across the literature. For example, studies of anxiety disor-
ders often include only a subsample of the eligible disorders—because
they are the focal target or because a thorough examination of the
individual disorders is too intensive. Prevalence might therefore be
defined in one study as the probability of having panic disorder or ago-
raphobia but in another study as the probability of having social pho-
bia or obsessive–compulsive disorder. This represents the “apples and
oranges” problem described in most textbooks (e.g., Borenstein,
Hedges, Higgins, & Rothstein, 2009, p. 379): If the underlying con-
struct varies to such a degree between studies, their aggregation rests
on questionable grounds.
The dominant solution has been to ignore variation in the disor-
ders measured (e.g., Goodman, Watson, & Stubbs, 2016; Guo et al.,
2016) or to include the number of disorders measured as a predictor
(e.g., Baxter, Scott, Vos, & Whiteford, 2013; Steel et al., 2014).
Although straightforward, either approach is likely to produce poor
estimates. The exclusion of individual disorders in a category‐level
estimate for a given study should negatively bias category prevalence.
Including the number of disorders as a predictor and generating the
prevalence of a study measuring all disorders may mitigate estimation
bias, but this approach assumes that eligible disorders are equally
prevalent—meaning that an increase of one disorder always influences
the category‐level prevalence in the same manner. Although poten-
tially true in some cases, it is often a questionable assumption.
An alternative approach is to perform a multivariate meta‐analysis
of the individual disorders accounting for the fact that disorder preva-
lences are likely to be correlated both within and between studies
(Jackson, Riley, & White, 2011). However, current multivariate
approaches cannot estimate the prevalence of a superordinate cate-
gory. This paper proposes a novel multivariate Bayesian approach that
estimates the prevalence of a superordinate category while providing
a more complete picture of its constituent disorders. We avoid aggre-
gating prevalence estimates that vary in their operationalization, and
instead model the prevalence estimates pertaining to the individual
disorders and their interrelations. These parameters can be used toestimate the probability of having at least one of those disorders. In
the following sections, we describe and then validate our model using
a case study and parameter recovery simulations.2 | METHODS
2.1 | Model
Put simply, our model uses aggregate and individual participant data
(IPD) to estimate the prevalence of each individual disorder and the
IPD to estimate the comorbidity between disorders. This portion of
our model is implemented using Version 2.16 of the Stan modeling
language (Stan Development Team, 2016) based on a binomial likeli-
hood with a probit link function to estimate the mean prevalence
and variability of each disorder across studies. Relevant code is avail-
able in Appendix A. In that appendix, Model 1 applies in the absence
of IPD and assumes that the probit‐transformed latent correlations
between the disorders are known. Model 2 uses IPD to estimate
the probit‐transformed latent correlations between the disorders,
incorporating uncertainty in these values into model estimates. In
either case, we use those parameters to simulate a large sample of
subjects from which to estimate the prevalence of having at least
one disorder. This is a separate step conducted using the R program-
ming language.
We define μs,d to be the probit‐transformed prevalence of disor-
der d in study s, and μs, * = (μs, 1,…, μs, D) to be the vector of all
probit‐transformed prevalences in study s. For the between‐study
portion of our model, we assume that μs,d follows a normal distribution
with mean θd and standard deviation τd, and μs, * follows a multivariate
normal distribution with correlations given by matrix ωB. The calcula-
tions were implemented using a Cholesky factor decomposition of
the correlation matrix to improve sampling efficiency, with a uniform
LKJ prior (Lewandowski, Kurowicka, & Joe, 2009) for the Cholesky
decomposition of ωB (see the Stan Reference Manual). Thus, we have
the following:
μs;* ∼ MVN θ*;ΣB
 
; ΣBdd′ ¼ τd × ωBdd′ × τd′ ; Chol ωBð Þ ∼ LKJ 2ð Þ:
Predictors could be incorporated by adding an additional term β
*
xs
to θ
*
where xs is the predictor value in study s.
For the probit‐transformed population prevalences (θd), we used a
mildly informative prior based on expert opinion. Because our case
study models rare disorders, we used a normal distribution
θd ∼ N(−1.88, 0.30
2),implying that population prevalences Φ(θd) rang-
ing from 0.6% to 10.0% would be considered probable (within 2 SD)
for any given disorder. For the between‐study estimates of standard
deviation for each disorder (τd), we employed a half‐normal distribu-
tion (truncated at 0) τd ∼ N(0,0.25
2) with a location parameter equal
to 0 and a standard deviation of 0.25, such that values larger than
0.5 would be unlikely. Presuming a mean prevalence of 3% for a given
disorder, this would mean that 95% of “true” study‐specific preva-
lences lie between 0.2% and 18.9%; we felt this to be a reasonable
range that balances the influence of the prior with convergence.
Models using broader priors on τd produced similar results, albeit with
less shrinkage, but did not converge as readily and were characterized
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available for any given disorder.
The within‐study model is broken into two parts—one dealing
with the aggregate data and the other dealing with the IPD. For stud-
ies where the IPD were unavailable, the number of participants with a
given disorder (ns,d) was modeled as arising independently from a bino-
mial distribution with sample size Ns equal to the sample size of study
s and probability defined earlier:
ns;d ∼ Binomial Φ μs;d
 
;Ns
 
:
For studies where the IPD were available, prevalence was esti-
mated using individual participant diagnoses. The binary (0 = no diag-
nosis, 1 = diagnosis) outcomes for each combination of participant
and disorder were modelled as dichotomizations of an underlying mul-
tivariate normal distribution, with a threshold at 0 and a latent corre-
lation matrix representing the relative comorbidity between
disorders (ωC), to which we again applied an LKJ prior. Parameters
for disorders not reported by that study were imputed within the
model itself. Here, we define eys,d,i as the underlying trait giving rise
to participant i in study s suffering from disorder d whereby ys,d,i as
the observed outcome.
ys;d;i ¼ eys;d;i > 0 ; eys;*;i ∼ MVN μs;*;ωC
 
; Chol ωCð Þ ∼ LKJ 2ð Þ:
We fit the model using Stan but estimate superordinate category
prevalence using a script built in R 3.3.1 (R Core Team, 2016; sample
code provided in Appendix B). Within this script, we first use the
posterior distribution from our model to generate a large number of
hypothetical participants, each taken from a different hypothetical
study that is also generated from the posterior distribution; we do this
by drawing 5,000 values from the posterior of μs,* and then drawing a
single participant (eys;*;i and therefore ys,*,i) for each. This procedure
makes use of the within‐study correlations between the disorders
(ωC) estimated from the IPD (if present) or other sources (e.g., esti-
mated elsewhere or arbitrarily assumed). The rows (i) of the resulting
matrix represent individual hypothetical participants whereas the col-
umns (d) represent individual disorders and each binary value indicates
whether hypothetical participant i was diagnosed with disorder d.
These binary values are summed for each row to simulate the number
of diagnoses for a given hypothetical participant, with the overall
prevalence representing the proportion of hypothetical participants
with one or more disorder. This approach estimates the probability
of a participant suffering from one or more AD while propagating
our uncertainty across parameters, including between‐study heteroge-
neity (τd). Prediction intervals for a new study are calculated in the
same manner, with the exception that only a single “true” prevalence
is estimated for each posterior sample (i.e., 5,000 hypothetical partic-
ipants drawn from the same hypothetical study).
2.2 | Implementation and sampling parameters
Stan is based on a variant of Markov Chain Monte Carlo sampling and
is described in greater detail elsewhere (Hoffman & Gelman, 2014).
Each model employed four independent chains. For the case study,
chains included 5,000 iterations minus a warm‐up period of 2,500resulting in 10,000 usable samples; for the simulations, chains included
1,000 iterations minus a warm‐up period of 500 resulting in 2,000
usable samples. We recommend the former but reduced this number
to make the simulations tractable; fewer samples in our simulations
should at worst handicap our estimates. Convergence was tested via
visual inspection and using the R‐hat statistic (in all cases R‐hat ≈ 1
and NEffective > 200, indicating convergence; Gelman & Hill, 2007).
We report all parameters in terms of their median value as well as
their highest density interval (HDI; Kruschke, 2014).
3 | RESULTS
3.1 | Case study of peripartum anxiety
3.1.1 | Case study description and parameters
We first illustrate our model using 10,033 participants from 18 articles
reporting prevalence estimates for at least one of six selected anxiety
and related disorders (AD; panic disorder, obsessive–compulsive disor-
der, generalized anxiety disorder, social phobia, specific phobia, and/or
posttraumatic stress disorder; remaining AD are omitted for the sake of
exposition). These data are summarized in Table 1. Of these data, we
retrieved IPD for 1,506 participants (Chaudron & Nirodi, 2010; Fadzil
et al., 2013; Fairbrother, Janssen, Antony, Tucker, & Young, 2016;
Fisher, Wynter, & Rowe, 2010; Matthey & Ross‐Hamid, 2011; Usuda
et al., 2016; Zar, Wijma, & Wijma, 2002). The average number of disor-
ders measured by a given study was 3.4; Figure 1 depicts the percent-
age of participants diagnosed with at least one disorder as a function of
the number of disorders measured. These studies represent a partial
sample from a meta‐analysis of AD within peripartum populations
(Fawcett, Fairbrother, Cox, White, & Fawcett, 2018). A partial sample
was selected for illustration purposes as it allowed us to focus on the
methodology itself rather than becoming lost in the details of the
included articles; for this reason, it is important that the present analy-
ses be used for demonstration purposes only. All but two studies
(Fisher, Tran, Kriitmaa, Rosenthal, & Tran, 2010;Wenzel, Haugen, Jack-
son, & Brendle, 2005) permitted calculation of a superordinate (i.e.,
“any disorder”) prevalence estimate—representing the probability of
having at least one of the disorders provided above; these studies
were excluded from Section 3.1.2 but included in Section 3.1.3.
They were selected despite the missing “any disorder” prevalence
estimates to highlight the fact that our model makes better use of
the available data.
3.1.2 | Univariate random‐effects models using “any
disorder” estimates
We first analyzed the “any disorder” prevalences, using a series of uni-
variate random‐effects models meant to emulate current practice. In
keeping with how these analyses have been conducted in the past,
we logit‐transformed the estimates for each study and aggregated
them using the rma function from the metafor package (Viechtbauer,
2010). We fit this model twice—once to the full data set, including
studies measuring any number of disorders, and again including only
studies measuring three or more disorders. All analyses are summa-
rized in Table 2. Clearly, requiring the inclusion of at least half of the
measured disorders increased the estimated prevalence. This might
FIGURE 1 Prevalence (%) of “any” (i.e., having at least one) anxiety
or related disorder (panic disorder, obsessive‐compulsive disorder,
generalized anxiety disorder, social phobia, specific phobia, and
posttraumatic stress disorder) plotted against the number of disorders
that were measured in that sample. Marker size represents the relative
sample size pertaining to each point, ranging from N = 24 to N = 2,202
TABLE 1 Descriptive statistics and prevalence estimates (%) reported by each study included in the case study
First author Year N Prevalence any Panic disorder OCD GAD Social phobia Specific phobia PTSD
Zar* 2002 453 21.9 1.3 0.2 0.9 2.7 18.3 1.3
Wenzel 2003 68 4.4 – – 4.4 – – –
Wenzel 2005 147 – 1.4 2.7 8.2 4.1 – –
Uguz 2007 434 3.5 – 3.5 – – – –
Rogal 2007 1100 3.0 – – – – – 3.0
Mota (Preg.) 2008 451 13.2 2.1 – 1.9 3.3 9.3 –
Mota (Post.) 2008 1061 15.0 4.0 – 2.3 2.5 10.2 –
Seng 2009 1581 7.9 – – – – – 7.9
Kersting 2009 65 0.0 0.0 0.0 – – 0.0 0.0
Fisher (Preg.) 2010a 199 – 1.5 – 10.6 – – –
Fisher (Post.) 2010a 165 – 4.2 – 11.5 – – –
Chaudron* 2010 24 37.5 4.2 29.2 – – 8.3 8.3
Fisher* 2010b 196 8.7 0.0 – 2.6 3.6 3.6 –
Uguz 2010 309 15.5 1.9 5.2 3.6 3.2 3.2 0.0
Matthey* 2011 171 14.0 2.9 2.9 11.1 4.1 – 0.6
Prenoveau 2013 2202 5.5 – – 5.5 – – –
Fadzil* 2013 175 6.3 5.7 0.0 0.0 0.6 – 0.0
Kim 2014 745 6.6 – – – – – 6.6
Usuda* 2016 177 3.4 1.1 1.7 0.0 1.1 – 0.6
Fairbrother* 2016 310 15.2 0.7 3.6 3.2 5.2 7.4 0.7
Note. Prevalence estimates from Matthey and Ross‐Hamid (2011) were calculated from raw data inclusive of additional subjects beyond those reported in
their article. Studies contributing IPD are marked with an asterisk (*) and “–” represent values that were not reported. IPD: individual patient data; Preg.:
pregnant group; Post.: postpartum group; OCD: obsessive–compulsive disorder; GAD: generalized anxiety disorder; PTSD: posttraumatic stress disorder.
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ders for inclusion; however, the only logical criterion would require
inclusion of all disorders. Unfortunately, such a criterion would
exclude most of the extant data; only three studies (Fairbrother
et al., 2016; Uguz, Gezginc, Kayhan, Sarı, & Büyüköz, 2010; Zar
et al., 2002) in the current sample provided “any disorder” prevalence
estimates inclusive of all six disorders.
Another approach is to use the number of measured disorders to
predict the prevalence of a hypothetical study measuring all disorders(e.g., Baxter et al., 2013). We again fit this model twice, once including
all studies and again including only studies measuring three or more
disorders. This approach predicts a higher prevalence estimate but is
unstable (see Sections 3.1.2 and 3.1.3). Importantly, whereas the
effect of number of disorders was significant in the former model
(P < 0.001), it was not significant in the latter model (P = 0.693)—likely
owing to reduced statistical power combined with range restriction.
This would be worsened should the number of disorders be treated
categorically (e.g., 1–2 disorders and 3–4 disorders;e.g., Baxter et al.,
2013) because converting continuous predictors into categorical ones
reduces statistical power (Gelman & Park, 2009).3.1.3 | Bayesian multivariate models
We next applied our model to the same data using the approach
described in Sections 2.1 and 2.2. From the posterior of this model,
we calculated the probability of having one or more, two or more,
and so forth disorders. As depicted in Table 3, this estimate is close
to those produced by either the univariate analysis of studies measur-
ing all disorders or the initial regression model. However, the HDI is
equivalent to or narrower than the confidence intervals from any of
the previous models—even though Bayesian confidence intervals for
aggregate effects are generally broader than their Frequentist coun-
terparts because the former take uncertainty in τ into account (in this
case for each disorder) whereas the latter assume that τ is known. This
reflects—in part—the greater ability of our Bayesian model to make
use of all data.
We next examined how well our model captured the data.
Figure 2 depicts observed and predicted disorder prevalence for each
TABLE 2 Prevalence estimates from the case study for each estimation procedure
Method No. of samples Disorder Prev. τProbit τLogit
BMV‐IPD 20 (7 IPD) Any 19 [15, 23] – –
Panic 2 [1, 3] .26 [.11, .45] –
OCD 3 [1, 5] .47 [.26, .71] –
GAD 4 [2, 6] .41 [.26, .60] –
Social Phobia 3 [2, 4] .11 [.00, .24] –
Specific Phobia 6 [3, 9] .36 [.19, .58] –
PTSD 2 [1, 3] .47 [29, .70] –
FRE 17 Any 9 [6, 13] .48 .77
FRE‐H 11 Any 13 [9, 18] .40 .64
FRE‐A 3 Any 18 [14, 23] .14 .22
FRE‐M 17 Any 16 [10, 23] .33 .53
FRE‐MH 11 Any 14 [7, 25] .44 .70
Note. Individual disorder estimates are also provided for our preferred multivariate approach. Estimates of τ were calculated in probit‐space for the multi-
variate Bayesian approach and in logit‐space for the univariate Frequentist approaches; for comparison, the logit values were converted into approximate
probit space via division by 1.6. BMV‐IPD: Bayesian multivariate w/individual patient data; FRE: Frequentist univariate; FRE‐H: as FRE but including studies
reporting at least three disorders; FRE‐A: as FRE but including studies reporting six disorders; FRE‐M: Frequentist univariate w/predictor; FRE‐MH: as FRE‐
M but including studies reporting at least three disorders.
TABLE 3 Probability of having at least 1, 2, 3, or 4 anxiety or related disorders (AD) within our case study as fit using a multivariate Bayesian
model with IPD (Model 2)
Number of disorders
1+ 2+ 3+ 4+
Prevalence 19% (15%, 23%) 5% (3%, 7%) 1% (1%, 2%) 0% (0%, 1%)
Prediction Interval (7%, 34%) (1%, 10%) (0%, 3%) (0%, 1%)
Note. The estimated probability of having 5+ disorders was negligible and therefore excluded. Prevalence estimates refer to the prevalence within a “typ-
ical” study whereas the prediction intervals indicate instead the range of credible values estimated from a new study similar to those included in the model.
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dictions. We also generated “any disorder” predictions for each study
in the same manner, with the “any disorder” prevalence defined as the
probability of having at least one of the disorders measured in that par-
ticular study. These predictions are provided in Figure 3 alongside the
reported “any disorder” prevalence values, where available. Despite
these data not entering our model, they are nonetheless well repre-
sented by the model's predictions.
The above analyses made use of mildly informative priors based
on expert knowledge. We repeated the analysis using less informative
(hence less realistic) priors. The uninformative prior placed on mean
prevalence estimates was based on a normal distribution with a mean
of −1.88 and a standard deviation of 1, calibrated such that mean
prevalences ranging from <0.1% to 54.8% would be considered prob-
able for any given disorder. For the between‐study estimates of stan-
dard deviation for each disorder (τd), the SD of the half‐normal was
increased to 0.35, meaning that values higher than 0.70 would be
uncommon. Presuming a mean prevalence of 3% for a given disorder,
a probit‐transformed standard deviation of 0.70 means that the “true”
prevalence within any given study might vary credibly from <0.1% to
31.6%. Despite these unrealistic prior expectations, the model output
remained largely unchanged—producing an overall estimate of 20%,
HDI95% (15%, 26%). Although the HDI has increased in size, this is
because the priors allocated credibility to the possibility that as manyas 80% of the participants in a typical study suffered from a given dis-
order, increasing uncertainty in τd.3.2 | Parameter recovery simulations
3.2.1 | General method
We next conducted three parameter recovery simulations comparing
our model against the approaches described in Section 3.1.2. The first
is based on the case study with respect to the number of samples, dis-
orders measured, participants per sample, and so forth. The second
and third explore how different levels of between‐study variability
influence performance across estimation approaches. Each simulated
dataset contained 20 studies with sample sizes randomly drawn from
an exponential distribution with a rate of .005 to which 100 was
added. A measurement process simulated the tendency for studies
not to measure all disorders by assigning each disorder a probability
for inclusion in that study. To ensure all disorders were represented,
the first two studies in each simulation were exempt from this
measurement process. The probability of having one or more of
the measured disorders was then calculated for each study given
the disorders measured; these values were used to test alternate esti-
mation approaches. The first seven studies in any given simulation
provided IPD.
FIGURE 2 Prevalence (%) for each anxiety or related disorder (panic disorder, obsessive‐compulsive disorder, generalized anxiety disorder, social
phobia, specific phobia, and posttraumatic stress disorder) and samplewithin our case study, simulated based on sample size and parameter estimates
derived from our model. Circles represent median prevalence estimates, and error bars represent HDI95%; the reported prevalence for each study is
denoted by an “X.” Predictions are provided for studies not measuring a given disorder, representing the probable prevalence of that disorder within
that sample. These studies can be identified by the absence of an “X” in the plot and the absence of a numerical prevalence value in the third column
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provided in Section 3.1.1. We used the median ωC and ωB matrices
from that model to emulate a realistic distribution of interdepen-
dencies. Similarly, the “true” prevalences for each disorder were
set at 1.5%, 2.0%, 2.5%, 3.5%, 4.0%, and 6.0%. Probit‐transformed
heterogeneity (τ) was derived from the values estimated in Section
3.2 (rounded to 0.50, 0.25, 0.45, 0.10, 0.40, and 0.35) and the
measurement probabilities were set to 50%, 50%, 70%, 50%, 70%,
and 40%.
Our second and third simulations explored the effect of heteroge-
neity by changing τ to 0.1 (low heterogeneity) or 0.4 (high heterogene-
ity) for all disorders. In both cases, we also made “true” prevalences
more diverse than in our case study (1.0%, 2.0%, 3.0%, 5.0%, 7.0%,
and 9.0%). Our goal in doing so was to evaluate how the predictorapproach would perform when the assumption of equal prevalence
across disorders was violated.
For each simulated data set, the prevalence of having one or more
of the individual disorders was estimated using the univariate
approaches presented in Section 3.1.1 (e.g., Baxter et al., 2013; Good-
man et al., 2016). We also used our Bayesian approach, first assuming
that the between‐disorder (ωC) correlation matrix was known (Model
1), then estimating this matrix from independent participant data
(Model 2). We fit the following to each simulated sample:
a.) FRE: Frequentist random effects model fit to the “any disorder”
prevalences ignoring the number of disorders measured;
b.) FRE‐H: as FRE but only including studies that reported at least
half of the disorders;
FIGURE 3 Prevalence (%) of having at least one anxiety or related disorder (panic, obsessive‐compulsive disorder, generalized anxiety disorder,
social phobia, specific phobia, and posttraumatic stress disorder) for each study within our case study simulated based on sample size and
parameter estimates derived from our model. Circles represent median prevalence estimates and error bars represent HDI95%; the reported
prevalence for each study is denoted by an “X.” Predictions are provided for studies for which the “any disorder” prevalence was unavailable,
representing the probable prevalence of having at least one disorder within that sample. These studies can be identified by the absence of an “X”
in the plot and the absence of a numerical prevalence value in the third column.
FAWCETT ET AL. 7 of 13c.) FRE‐M: Frequentist random effects model fit to the “any disor-
der” prevalences including the number of disorders measured
as a predictor and estimating the prevalence of a study measur-
ing all disorders;
d.) FRE‐MH: as FRE‐M but only including studies which reported at
least half of the disorders;
e.) BMV‐K: Bayesian multivariate approach fit to the individual dis-
order estimates, using only aggregate data and assuming ωC is
known (Model 1);
f.) BMV‐IPD: Bayesian multivariate approach fit to the individual
disorder estimates, using both aggregate and IPD and estimating
ωC from the model (Model 2);
For each model including a predictor, we also recorded the asso-
ciated P value. We ran each simulation 100 times—with every iteration
representing a simulated meta‐analysis. Iterations required ~6 hr each.
For each simulation study, the “true” prevalence of having at least oneFIGURE 4 Prevalence (%) of having one or more disorder within eac
described in text for Simulation 1 (τ and prevalence based on case study),
prevalence is represented by a dotted line within each plotdisorder was estimated by simulating IPD for 10,000 participants—
each from a separate study—10,000 times, calculating the overall
prevalence for each and taking the median.3.2.2 | Simulation results
Each panel of Figure 4 depicts the prevalence of having at least one
disorder as estimated by each procedure within each simulation. The
“true” prevalence for each is depicted by a dotted line; these “true”
prevalences depend on individual disorder heterogeneity and hence
differ across simulations.
Neither ignoring the number of disorders in each study nor includ-
ing them as a predictor is adequate. Ignoring variation in the number
of measured disorders tended to catastrophically underestimate the
“true” prevalence. This underestimation was mildly improved by
requiring that a nominal number of disorders be measured for inclu-
sion; we included as our cutoff the midpoint of the number of disor-
ders measured, but this procedure should approach an unbiasedh simulated meta‐analysis using each of the estimation approaches
Simulation 2 (τ = 0.1),s and Simulation 3 (τ = 0.4); the “true”
TABLE 4 Coverage statistics and mean confidence interval width
(defined as the difference between upper bound and lower bound)
within each simulated sample for each estimation approach and pre-
sented separately for Simulation 1 (τ and prevalence based on case
study), Simulation 2 (τ = 0.1), and Simulation 3 (τ = 0.4)
Coverage (%) Mean width (%)
Simulation 1
FRE 0 (0) 6
FRE‐H 16 (4) 7
FRE‐M 95 (2) 17
FRE‐MH 94 (2) 17
BMV‐AG 97 (2) 7
BMV‐IPD 98 (1) 7
Simulation 2
FRE 0 (0) 5
FRE‐H 2 (1) 5
FRE‐M 95 (2) 11
FRE‐MH 99 (1) 10
BMV‐AG 99 (1) 4
BMV‐IPD 100 (0) 4
Simulation 3
FRE 0 (0) 8
FRE‐H 13 (3) 9
FRE‐M 99 (1) 22
FRE‐MH 96 (2) 22
BMV‐AG 89 (3) 8
BMV‐IPD 94 (2) 8
Note. Value in brackets represents the Monte Carlo error for that estimate;
all Monte Carlo errors for mean width are less than 0.5% (maximum of
0.49% and minimum of 0.05%) and therefore would have rounded to 0.
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number of possible disorders. Imposing this limitation necessarily
decreases the number of studies available for analysis, making it inef-
ficient. Including the number of disorders as a predictor resulted in an
unbiased but variable estimate. A slight positive bias emerged in Sim-
ulations 2 and 3, where the prevalences differ from one another to a
greater degree, and the variability of the estimate scaled with increas-
ing heterogeneity.
In contrast, the Bayesian models produced efficient estimates
with no discernable bias when heterogeneity was moderate or low
(Simulations 1 and 2), with a slight negative bias for BMV‐K (median
bias of approximately −1%) when heterogeneity was high (Simulation
3). This bias is slight, so we do not wish to over‐interpret; nonetheless,
we speculate that it arises because all values of τ within this simulation
are near the upper range of our prior. Therefore, a small amount of
shrinkage is expected. Estimation of τ has consequences for the over-
all prevalence in part because of the use of a normal distribution on
the probit scale: for a fixed probit‐transformed prevalence of less than
0 (corresponding to prevalences below 50%), increasing τ increases
both left and right tails on the probit scale, but this has a greater
impact for the right tail on the probability scale. As a result, larger τ
means larger prevalence (assuming μ is unchanged). Inspection of the
posterior estimates across our simulations supports this conviction—
with the τ for each disorder being underestimated on average by
0.05 (results not shown). Such underestimation is negligible for indi-
vidual disorders but could aggregate to produce a slight bias overall.
BMV‐IPD was unaffected.
Our model is further supported by coverage estimates and confi-
dence interval widths provided in Table 4. These estimates represent
the percentage of samples wherein the confidence or highest density
intervals included the “true” prevalence value. The predictor model
and the Bayesian model maintained nominal coverage across all simu-
lations (with the exception of BMV‐K in Simulation 3) whereas the
simple univariate models performed comparatively poorly. Confidence
interval widths from the predictor model were two to three times
wider than from the other methods.
Finally, for Simulation 1, the statistical power for testing the slope
for the number of measured disorders was relatively high (86%) in the
model inclusive of all studies but only moderate (52%) when studies
were required to measure half of the disorders for inclusion. The same
pattern was observed in Simulations 2 and 3, with the exception that
power was universally high when heterogeneity was low (99% and
90% for FRE‐M and FRE‐MH, respectively) and more variable when
heterogeneity was high (83% and 33% for FRE‐M and FRE‐MH,
respectively).
Differences in the precision of estimates from FRE‐M and BMV‐
IPD are larger in the simulations than in the case study. Because the
BMV‐IPD approach uses individual disorder estimates, the sample on
which our case study is based includes a preponderance of single
disorder papers that are otherwise rare in this type of analysis (e.g.,
Goodman et al., 2016) where studies measuring multiple disorders
are preferred. Our simulations match the overall mean number of dis-
orders measured from the case study but do not specifically reflect
this idiosyncratic quality. Single disorder estimates will be less vari-
able (they are affected by heterogeneity from only a single disorder)and would also have a high degree of influence in the predictor anal-
ysis, stabilizing the slope and therefore increasing precision of the
estimate. Additional simulations support this interpretation, showing
that meta‐analyses forced to emulate the distribution of disorders
measured from the case study produce more precise estimates for
the predictor approaches due to reduced uncertainty in the slope
(results not shown). Importantly, inclusion of so many single disorder
estimates is uncommon and still rests on the assumption that disor-
ders are equally prevalent and comorbid. Our model outperforms a
purely predictor based model—even under these conditions—just
not as drastically.4 | DISCUSSION
4.1 | Advantages
4.1.1 | More efficient use of data
Our model permits the combination of more information than is pos-
sible with a univariate approach. For example, the inclusion of single
disorder studies in a univariate analysis offers no specific advantage
and is liable to bias aggregate estimates. In our model, single disorder
studies inform the prevalence of the disorder in question—which in
turn improves the precision of our category‐level estimate. Further,
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—not all studies provide workable category‐level estimates, either due
to inclusion of ineligible disorders (e.g., depression) or omission of the
“any disorder” prevalence. Therefore, the number of studies eligible
for inclusion is higher for our model, and the data obtained are put
to better use.4.1.2 | Access to an informative posterior
distribution
Our model produces a posterior distribution representing the combi-
nation of all pertinent knowledge. In addition to prevalence estimates
for the individual disorders, this posterior provides the probability of
any arbitrary event or confluence of events. For example, Table 3 pro-
vides the probability of having any number of disorders. It is possible
to use the same approach to explore comorbidity. If a clinician knew
that a given participant had been diagnosed with panic disorder, they
might like to know the odds of that participant suffering from general-
ized anxiety disorder. This can be calculated from the posterior using
the conditional probability of having generalized anxiety disorder
given a diagnosis of panic disorder. Based on the case study, this
probability is 20%, HDI95% (6%, 39%), and meaning that peripartum
participants with panic disorder have a one in five chance of having
generalized anxiety disorder. Prediction intervals representing the
range of possible “true” values across the distribution of samples
similar to those included in the present analysis can also be calculated
(in the current case: HDIPI95% [0%, 58%]). One could likewise choose
to calculate the probability of having any number of specific disorders
(e.g., What is the probability of having a diagnosis of generalized
anxiety disorder, panic disorder, and social phobia?). The possible
questions addressable using the output of this model are limited only
by imagination and need.4.1.3 | Easy handling of dependencies between
samples
One common challenge that faces meta‐analysts is dealing with multi-
ple samples from the same study or population; such estimates are
dependent on one another in a manner that will artificially deflate
uncertainty in the aggregate prevalence estimate if not addressed.
For the Frequentist approaches described in Section 3, this depen-
dency is often ignored; however, they are readily handled in our
Bayesian approach—and in fact, complex random structure could be
implemented. Our case study included two studies with multiple sam-
ples (Fisher, Tran, et al., 2010; Mota, Cox, Enns, Calhoun, & Sareen,
2008), which were handled by estimating a single “true” prevalence
used by all samples from the study in question.4.1.4 | Use of prior knowledge
Our approach incorporates expert knowledge into the model to
improve estimation. As demonstrated earlier, the improvement in the
precision of an estimate due to a reasonable (but skeptical) prior can
be substantial. Given the availability of expert knowledge, this would
seem to be an easy way to improve model efficiency.4.2 | Potential limitations
4.2.1 | Assumes access to IPD
The first limitation is that we assume access to IPD from which to esti-
mate the within‐study correlations amongst the individual disorders
(ωC). Without those data, our model must assume that ωC is known
(Model 1), which is uncommon. Although gathering individual data
can be difficult, the improved accuracy is worth the effort. This effort
could be lessened if those reporting epidemiological studies shared
their data or provided a table summarizing each participant suffering
from at least one disorder, with a list of each diagnosis they received
(e.g., 5 × panic disorder, 2 × panic disorder + posttraumatic stress
disorder; e.g., Zar et al., 2002).
4.2.2 | Assumes homogeneity of within‐study corre-
lations between disorders (ωC)
This assumption was made partially to simplify our model but also
because we do not believe that IPD from a broad enough sample of
studies is generally available to estimate heterogeneity amongst the
correlations. We highlight this as a potential area for future
development.
4.2.3 | Assumes studies are sampled from a larger
population
Interpretation of any meta‐analysis—including those based on the cur-
rent approach—is complicated by the presence of heterogeneity. This
is because samples included in the model are assumed to be drawn
randomly from a broader population of potential samples. Therefore,
consideration must be given to the populations being studied, and
the results must be interpreted in light of the distribution of prevalence
estimates (e.g., using prediction intervals).
4.2.4 | Assumes generality based on a single
application
Current findings suggest our model to be an improvement over
existing approaches; however, these findings (including the parameter
recovery simulations) are based on a particular application in the field
of Psychology. Although we expect fully that our model will generalize
to other topics, as with all new techniques, it is possible that the
observed benefits may be linked to the circumstances of the selected
case in unexpected ways. Future applications to other fields will deter-
mine whether this is true.4.3 | Alternative approaches and extensions
Although we demonstrate our multivariate Bayesian model to be in
many ways superior to the univariate Frequentist models previously
used to estimate the prevalence of a superordinate category (e.g.,
Goodman et al., 2016), there are certainly alternative approaches
to address this problem. For example, one could use the expectation
maximization algorithm to estimate the prevalence of each of the
individual disorders, treating unmeasured disorders within a given
sample as missing data. One could also implement a multilevel, mul-
tivariate Frequentist model (e.g., using metafor; Viechtbauer, 2010)
to estimate the prevalence of the individual disorders. However, in
10 of 13 FAWCETT ET AL.either case, it would be necessary to combine the individual disorder
estimates into an estimate of the superordinate category prevalence.
This would most likely involve a simulation procedure similar to that
described in Appendix B—and would necessitate inclusion of IPD to
estimate the comorbidity across disorders. For that reason, we do not
expect either solution to be simpler than the current approach and nei-
ther would not benefit from most strengths detailed earlier. In short,
whereas other approaches may be preferable under certain circum-
stances, we believe that complex evidence synthesis often benefits
from a Bayesian approach such as ours (e.g. Ades & Sutton, 2006).
Even so, the current model represents only an initial step towards
developing a general method for estimating the prevalence of a super-
ordinate category. For that reason, there are many possible exten-
sions. As one representative example, our model could be modified
to address bias caused by variation in measurement or selection across
studies, perhaps using bias modelling methods such as those of
Turner, Spiegelhalter, Smith, and Thompson (2009). This would permit
quantification of—and adjustment for—biases due to variation in the
quality of the included studies. This would reflect a clear improvement
and is a potential target for future development.5 | CONCLUSION
Estimating the prevalence of a superordinate category of disorders
based on studies with differing operationalization of that category is
both common and ill‐advised (e.g., Baxter et al., 2013; Goodman
et al., 2016; Guo et al., 2016; Steel et al., 2014). We propose instead
a Bayesian model using IPD that we have shown to produce unbi-
ased, efficient estimates where other approaches are biased and/or
inefficient. The accurate estimation of disease prevalence is of
profound clinical importance, because it serves to guide public policy.
To use our case study as an example, a shift from 9% to 19% in the
estimated prevalence of peripartum AD means a change from
one in 10 to one in five peripartum women suffering from one or
more AD. Such a shift has implications for the allocation of public
funds and even screening procedures. For this reason, we believe that
the current Bayesian approach will have real clinical importance and
hope that the present article will encourage future meta‐analysts to
adopt a similar approach when estimating superordinate category
prevalence in the future.
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APPENDIX A: MODEL CODE
Below is the Stan code necessary to fit Model 2 reported in text; this
code can be extended to incorporate predictors by adding a vector of
slopes to the parameter section that is then multiplied by the predictor
and added to each of the disorders within the transformed parameters
section (see commented lines). To fit Model 1 reported in text, simply
delete all lines corresponding to the individual participant data model.
If you have any comments or questions pertaining to this code, you
should contact the first author (jmfawcet@gmail.com).
data {
// General section
int<lower=1> nstudies; // Number of unique studies
int<lower=1> ndisorders; // Number of unique dis-
orders
//
// Aggregate section
//
// Number of observations (one per study per dis-
order)
int<lower=1> nobs;
// Study IDs
int<lower=1,upper=nstudies> studyid[nobs]; // s
// Sample sizes
int<lower=1> samplesize[nobs]; // N_s,d
// Number of diagnoses
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// Disorder IDs
int<lower=1,upper=ndisorders> disorderid[nobs];
// d
//
// IPD section
//
// Number of observations (one per individual per
disorder)
int<lower=1> ipd_nobs;
// Study IDs
int<lower=1,upper=nstudiesgt;
ipd_studyid[ipd_nobs]; // s
// 1 = diagnosis, 0 = no diagnosis, -1 = missing data
int<lower=-1,upper=1> y[ipd_nobs, ndisorders];
// y_s,d,i
//
// (Optional) Predictor Section
// Note: Assumes Predictors are centred
//
// Predictor for Aggregate Section
// real moderator[nobs];
//
// Predictor for IPD Section
// real ipd_moderator[ipd_nobs];
}
parameters {
//
// Aggregate section
//
vector[ndisorders] probit_prevalence; // theta_d
matrix[nstudies,ndisorders]
zstudy_probit_prevalence;
cholesky_factor_corr[ndisorders] L_Omega; //
cholesky of omega_B
vector<lower=0>[ndisorders] tau; // tau_d
//
// IPD section
//
cholesky_factor_corr[ndisorders] ipd_L_Omega; //
cholesky of omega_C
// nuisance that absorbs inequality constraints
real<lower=0,upper=1> u[ipd_nobs, ndisorders];
//
// (Optional) Predictor section//
// vector[ndisorders] slopes;
}
transformed parameters {
vector[ndisorders]
study_probit_prevalence[nstudies]; // mu_s,d
for(i in 1:nstudies) {
study_probit_prevalence[i] = probit_prevalence
+ tau .* (L_Omega *
to_vector(zstudy_probit_prevalence[i]));
}
}
model {
//
// Aggregate section
//
L_Omega ~ lkj_corr_cholesky(2);
// SDs of .5 or less are common
tau ~ normal(0,.25);
to_vector(zstudy_probit_prevalence) ~ normal(0,
1);
// Mean disorder prevalences are likely to be in
range 0.6%-10%
probit_prevalence ~ normal(-1.88, .3);
//
// (Optional) Prior for Predictor
//
// slopes ~ normal(0,1);
// Assumes Independence w/i studies – incorrect,
but necessary to
// model the aggregate data for which IPD is
unavailable
for(i in 1:nobs) {
count[i] ~ binomial(samplesize[i],
Phi_approx(study_probit_prevalence[studyid[i]]
[disorderid[i]]));
//
// If including predictors instead use…
//
// count[i] ~ binomial(samplesize[i],
//
Phi_approx(study_probit_prevalence[studyid[i]]
[disorderid[i]] +
// slopes[disorderid[i]]*moderator[i]));
}
//
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ipd_L_Omega ˜ lkj_corr_cholesky(2);
// implicit: u is iid standard uniform a priori
// compute likelihood contribution for each indi-
vidual and each
// disorder conditional on previous disorders for
this individual
for (j in 1:ipd_nobs) {
vector[ndisorders] z;
real prev;
prev = 0; // prev is a correction on the probit
scale to allow for values of previous disorders for this
individual
for (d in 1:ndisorders) {
// Phi and inv_Phi may overflow and / or be inac-
curate
real bound; // threshold on Phi(y*)
bound = Phi(-
(study_probit_prevalence[ipd_studyid[j]][d] +
prev) / ipd_L_Omega[d,d]);
// If including predictors instead use…
//
//
// bound = Phi( -
(study_probit_prevalence[ipd_studyid[j]][d] +
// slopes[d]*ipd_moderator[j] + prev) /
ipd_L_Omega[d,d]);
if (y[j,d] == 1) {
target += log1m(bound); // log-likelihood
increment
// Ensures that y* is drawn from its conditional
distribution
// given previous y values
real t;
t = bound + (1 - bound) * u[j,d];
z[d] = inv_Phi(t); // implies latent variable
is positive
}
else if (y[j,d] == 0) {
target += log(bound); // log-likelihood incre-
ment// Ensures that y* is drawn from its conditional
distribution
// given previous y values
real t;
t = bound * u[j,d];
z[d] = inv_Phi(t); // implies latent variable
is negative
}
else {
z[d] = inv_Phi(u[j,d]); // latent variable is
unbounded
}
if (d < ndisorders) prev = ipd_L_Omega[d+1,1:d] *
head(z, d);
// Model implies z is truncated standard normal
// thus utility — mu + ipd_L_Omega * z —
// is truncated multivariate normal; the above code
// gives the conditional distribution of y* given past
// y* values
}
}
}
generated quantities {
// Between-study correlation matrix
corr_matrix[ndisorders] Omega; // omega_B
// Between-disorder correlation matrix
corr_matrix[ndisorders] ipd_Omega; // omega_C
//
// Aggregate section
//
Omega =
multiply_lower_tri_self_transpose(L_Omega);
//
// IPD section
//
ipd_Omega =
multiply_lower_tri_self_transpose(ipd_L_Omega);
}
APPENDIX B: R CODE NECESSARY TO
GENERATE OVERALL PREVALENCE
ESTIMATES
The R code necessary to generate the overall prevalence estimates of
the models reported in Appendix B is included as a separate file.
